Addressing a critical need in prostate cancer treatment, BDR Pharmaceuticals introduces BDENZA, world’s first oral solution in 32mg/mL designed for the management of prostate cancer. BDENZA will be available at Rs. 27,000 for 150mL. This innovative formulation marks a significant step forward in providing an effective dosage form, with lesser side effects in comparison to existing oral dosage forms of Enzalutamide. The Dose reduction owing to tolerability of the product by patients is a big advantage of this oral solution, as dose regimen can be adjusted based on the volume of consumption. This flexibility is absent in existing oral dosage forms of Enzalutamide.
Prostate cancer is a growing concern, with an estimated 1.2 million new cases diagnosed globally each year and an estimated 375,000 deaths, according to the WHO. Earlier it was the 8th most common cancer in males in the 1990s, but now it moved to 3rd place by 2015 in India. In India, a total of 37,416 cases of prostate cancer were reported in 2016. It was projected to increase to over 47,000 cases by 2025. Considering majority of the population suffering from prostate cancer is geriatric population, certain aspects like taking high dosage medication is difficult. Recognizing the significant challenge faced by Geriatric patients/ Old patients. BDR Pharmaceuticals introduced affordable alternative medication formulation.
Dr. Aravind Badiger Director, Technical Formulation, “Changing how we treat prostate cancer, BDENZA ORAL SOLUTION brings a mix of benefits to make things better for patients. It gives a strong 160mg dose in just one small 5ml serving, so there’s less hassle associated with lots of pills. Unlike fixed-dose tablets, doctors can adjust the dosage to fit each patient better. This oral solution is gentle on the stomach, avoiding issues like nausea. Plus, it is sugar-free and tastes good, making it easier for patients, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent”
Raheel Shah, BDR Group Director (Business Development), expresses the company’s commitment: BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability.”
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide. BDR Pharma is proud to lead the way in making advanced and affordable treatments available, contributing to a brighter future for cancer patients in India and beyond.
BDR Pharmaceuticals remains committed to delivering affordable healthcare solutions for all. This affordability will ensure wider accessibility for Indian patients, making a substantial difference in their fight against prostate cancer.